About Mogens Gisselbaek, MD, MSc
Founder of Gisselbaek Consulting. Fractional CMO, Medical Director and senior medical consultant for biotech, medtech, specialty pharma and life science investors.
I help companies access senior clinical and medical leadership at the moments where development decisions define enterprise value. After more than two decades in global pharma, biotech and medtech, I founded Gisselbaek Consulting to support organisations that need senior-level ownership of strategy and execution without necessarily hiring a full-time CMO or Medical Director.
Selected leadership experience
- Chief Medical Officer in an orthopaedic biotech.
- Senior Director in Global Clinical Drug Development at Novo Nordisk.
- Medical Director and Medical Affairs leader in international companies.
- Leadership of global clinical development programmes across Phase I-IV.
- Built and strengthened Medical Affairs organisations in multiple company contexts.
- Accountability for medical and scientific review in high-visibility, compliance-sensitive environments.
Perspective on value creation
Different innovation models require different development logic. Internal innovation, external innovation, biotech financing, medtech evidence generation, investor due diligence and partnerships each require a different balance of risk, evidence, governance and execution. The objective is always the same: maximise enterprise value by making the development path credible, decision-ready and executable.
How I work
I am hands-on, collaborative and pragmatic. I integrate with executive teams, clinical teams, CROs, agencies and advisors, and I take responsibility for decisions, progress and external credibility. My work is structured around what matters most for patients, regulators, payers, prescribers, investors and the company’s next value inflection point.
Typical situations
- A biotech is preparing for first-in-human, proof of concept or the next financing round.
- A medtech company needs a stronger clinical evidence strategy.
- A specialty pharma company needs senior Medical Affairs capacity before launch or expansion.
- An investor or board needs independent medical and clinical due diligence.
- A company needs interim Medical Director or fractional CMO support while building the permanent organisation.
Let’s talk if you are building, scaling, financing or repositioning a biotech, medtech or specialty pharma company and need senior clinical or medical leadership.